1999 Fiscal Year Final Research Report Summary
BASIC RESEARCH OF NEW GENE THERAPY FOR PROSTATE CANCER WITH GROWTH FACTOR RECEPTOR
| Project/Area Number |
10671474
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
MATSUBARA Akio HIROSHIMA UNIVERSITY, MEDICAL HOSPITAL UROLOGY, RESEARCH ASSOCIATE, 医学部・附属病院, 助手 (10239064)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MITA Kouji HIROSHIMA UNIVERSITY, FACULTY OF MEDICINE UROLOGY, RESEARCH ASSOCIATE, 医学部, 助手 (70304425)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Keywords | FGF / PROSTATE CANCER / GENE THERAPY |
|---|
| Research Abstract |
We have been investigating the potential roles of fibroblast growth factor receptors (FGFRs) in growth control of prostate tumors. Consequently we have recently found that hormone-dependent prostate tumor cells express FGFR2IIIb which mediates response to stromal-derived growth regulator FGF-7, while they lose the expression of FGFR2IIIb during progression from hormone-dependent to hormone-independent and escape the growth regulation by FGF-7. Instead the hormone-independent prostate tumor cells express FGFR1 and acquire autonomy. The results indicate that both restoration of FGFR2IIIb and deactivation of FGFR1 may result in a treatment of hormone-refractory prostate cancer. Thus, we induced the expression of FGFR2IIIb in hormone-independent rat prostate tumor cells by transfection. As a result, the transfected cells regained communication with stroma and not only showed reduced population growth rates, but also recovered cytokeratin expression and gland-like morphology specific to hormone-dependent tumors. We also transfected hormone-independent rat prostate tumor cells with kinase-defective FGFR1 to deactivate the endogenous FGFR1 by dominant-negative effect. As a result, in vivo growth of the transfected cells was similar to that of FGFR2IIIb-introduced cells.
|
